Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parasternal block to prevent hypertensive and tachycardia episodes during sternotomy in CABG
2018-002842-35Phase 4Completed
- Sponsor
- CMC Ambroise Paré
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ropivacaine in coronary arteriosclerosis, sponsored by CMC Ambroise Paré. Primary endpoint: Maximal dose of remifentanil required during key surgical stages. Started Aug 2018; status: completed.
02
Drugs
ropivacaine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2018-002842-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002842-35.